Arthrosamid
Arthrosamid and Contura Orthopaedics are partners with England Athletics
An inspiring new commercial partnership which will see key messages about the benefits of non-surgical alternatives for the treatment of pain associated with knee osteoarthritis (OA) disseminated across a membership base of around 1800 affiliated grassroots clubs.
With a proposed target audience of runners and athletes aged 35+, suffering with knee pain and / or OA (as well as coaches and physiotherapists associated with the organisation), England Athletics is ideally placed to help Contura Orthopaedics reach out to those in need of reliable education and information about the potential benefits of the novel hydrogel injection, Arthrosamid®.
The collaboration will include workshops, webinars and in-person events, as well as the recruitment of a new panel of Ambassadors and will shine a light on the importance of emerging innovation in the osteoarthritis ‘space’, whilst raising awareness of treatment options designed to maintain mobility – and crucially, to help keep people running!
An insightful new survey conducted by England Athletics* as part of this project revealed that almost 9 in 10 of the athletes questioned claimed to have experienced knee pain which prevented them from running, with the majority acting in the form of rest (88%) painkillers (64%) or physiotherapy (63%). And, over half (51%) of those asked admitted they would consider paying for treatment for knee pain if it meant avoiding surgery.
CEO of England Athletics, Chris Jones, said;
"Injury and chronic pain can be the curse of any athlete, and as we know—both anecdotally and from our recent survey—they can be a real source of frustration, sometimes even impacting mental health.
I’m delighted to see how our community engages with this project as we share interesting and empowering information. By working together, we hope to empower our members with knowledge that enables them to continue their love for sport."
Arthrosamid® offers long-lasting, proven pain relief 1,2 with a single injection and has the potential to redefine the current care pathway for managing knee OA, which affects around 5.4 million people in the UK.3 Despite this large suffering population, there has been very little innovation in the range of OA treatments on offer to help patients – until now.
And, as such, Arthrosamid®, has been hailed by clinicians as an exciting ‘game changer’; the first and only injectable hydrogel proven to help patients with knee OA, offering a real alternative to surgery.
Eligible patients receive a single injection into the knee joint space – a 6ml dose of Arthrosamid® (which permanently combines with the knee’s synovial tissue4) – decreasing joint stiffness, diminishing pain, improving the function of the knee affected by knee osteoarthritis, and enhancing quality of life.1,5,6
* England Athletics knee injury survey, Nov 2024, N=131
Rakesh Tailor, CEO of the Contura Group, comments;
"We’re always striving to find new ways of keeping people equipped with the knowledge they need to make informed choices about their personal, treatment pathway."
"Our team at Contura Orthopaedics is hugely looking forward to this partnership developing over the coming months and speaking to a new generation of athletes about positive approaches to managing knee pain."
Encouragingly, new four-year data presented in September 2024 at the European Orthopaedic Research Society Meeting (EORS) in Aalborg, Denmark demonstrated the long-term efficacy of the hydrogel injection – showing that a single dose maintained a statistically significant reduction in pain in patients with knee OA four years after treatment.1
Website and Social Media
References
- 1Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024.
- 2Bliddal, H., et al. (2024) 3-year follow-up from a randomized controlled trial of intra-articular polyacrylamide hydrogel injection in subjects with knee osteoarthritis. Poster LB-31, OARSI 2024 World Congress on Osteoarthritis.
- 3Versus Arthritis, 2023
- 4Christensen, L., et al. (2016). Histological Appearance of the Synovial Membrane after Treatment of Knee Osteoarthritis with Polyacrylamide Gel Injections: A Case Report. Journal of Arthritis. Vol 5: 217.
- 5Bliddal, H., et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Month Prospective Study. J Orthop Res Ther. Vol 6 (2). 1188. ISSN 2575-8241
- 6Bliddal, H., et al. (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid: A randomised controlled study. Osteoarthritis and Cartilage, Vol 30, S1, S371.